PPAR激动剂在治疗非酒精性脂肪性肝病中的应用前景

Application prospect of peroxisome proliferator-activated receptor agonists against non-alcoholic fatty liver diseases

由于肥胖症和2型糖尿病患者越来越多,非酒精性脂肪性肝病(NAFLD)也呈现逐年上升趋势。NAFLD可引起肝硬化和肝癌等并发症,严重威胁公众健康,目前尚无有效治疗NAFLD及其并发症的药物。肝脏甘油三酯聚集是NAFLD的重要标志,过氧化物酶体增殖物活化受体(PPAR)可参与脂代谢、糖代谢以及炎症的调控。本文综述了PPAR参与NAFLD的可能作用机制以及治疗NAFLD的PPAR激动剂的研究进展。

Nowadays,non-alcoholic fatty liver disease（NAFLD）is increasing with prevalence of obesity and type-2 diabetes.Therefore,NAFLD deeply influences public health.NAFLD can cause many complications,such as cirrhosis and liver cancer.At present,no effective drug has been approved for NAFLD and its complications.Peroxisome proliferator-activated receptor（PPAR）,activator of nuclear receptor ligands,participates in regulation of lipid metabolism,glucose metabolism and inflammation.This review summarizes possible mechanism of PPAR participated in NAFLD and study advances in PPAR agonists against NAFLD.